open access
Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia
Affiliations- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
- Department of Clinical Transplantology, Medical University of Lublin, Lublin, Poland
open access
Abstract
Abstract
Keywords
chronic lymphocytic leukemia, ibrutinib, platelet function
About this articleTitle
Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia
Journal
Issue
Article type
Short communication
Pages
416-420
Published online
2022-11-07
Page views
1087
Article views/downloads
89
DOI
10.5603/AHP.a2022.2056
Bibliographic record
Acta Haematol Pol 2022;53(6):416-420.
Keywords
chronic lymphocytic leukemia
ibrutinib
platelet function
Authors
Bożena Sokołowska
Dariusz Jawniak
Aleksandra Nowaczyńska
Agnieszka Szymczyk
Ewa Wąsik-Szczepanek
Marek Hus
References (15)- Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15(5): 835–847.
- Wang J, Zhao A, Zhou H, et al. Risk of bleeding associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2020; 11: 580622.
- Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019; 133(12): 1298–1307.
- Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019; 184(4): 558–569.
- Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100(12): 1571–1578.
- Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124(26): 3991–3995.
- Rigg RA, Aslan JE, Healy LD, et al. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am J Physiol Cell Physiol. 2016; 310(5): C373–C380.
- Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015; 29(4): 783–787.
- Pulte D, Olson KE, Broekman MJ, et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med. 2007; 5: 23.
- Alberelli MA, Innocenti I, Sica S, et al. PO-54 — clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia. Thromb Res. 2016; 140(Suppl 1): S196.
- Dmitrieva EA, Nikitin EA, Ignatova AA, et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020; 18(10): 2672–2684.
- Kazianka L, Drucker C, Skrabs C, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia. 2017; 31(5): 1117–1122.
- Alberelli MA, Innocenti I, Autore F, et al. Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients. Haematologica. 2018; 103(3): e119–e122.
- Santoro RC, Falbo M, Levato L, et al. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases. Blood Coagul Fibrinolysis. 2021; 32(2): 159–161.
- Raz MA, Arnason J, Bairey O, et al. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Br J Haematol. 2020; 189(2): e31–e33.